Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has recently launched Belviq as IMS Health, Mylan, Inc. (NASDAQ:MYL)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) a biopharmaceutical company which engages itself to discover, develop and commercialize novel drugs that targets the G protein-coupled receptors in the therapeutic areas of central nervous system, inflammatory, metabolic and cardiovascular diseases.
Arena has announced that the company has applied for approval for its anti-obesity drug named Belviq from the Canadian regulatory. The company has earlier in the month of June received approval almost after one year from the U.S. Food and Drug Administration.
The application was made by Eisai Inc., Arena’s partner marketing and commercialization and its Canadian subsidiary Eisai Ltd who has paid $500,000 to Arena and has to also pay from the sales amount received from the said drug.
Belviq is a drug to treat adult patients who have symptoms of increased physical activities or are overweight with the presence of at least one cardiovascular risk factor and is used as an auxiliary to a reduce calorie diet is being evaluated in Canada.
Jack Lief, Arena’s president and CEO said that nearly 60% of the Canadians are either overweight or obese and there are only few treatment options for them despite of regular dieting and exercises. He hopes that on receipt of approval from the Canadian Health Care for the New Drug Submission for Belviq physicians can help their patients and motivate them to reduce their weight and manage it efficiently.
The investors of the company were excited with the recently launched Belviq as IMS Health has reported that the said drug has filled 1,087 prescriptions in just three days after its launch.
Mylan, Inc. (NASDAQ:MYL) is a company that engages in developing, manufacturing, marketing, licensing, and distribution of generic and branded pharmaceuticals, specialty and active pharmaceutical ingredients across the world.